Beactica Announces Fragment-Based Drug Discovery Agreement
29-Apr-2011
- Sweden
"We are pleased to work with Janssen and look forward to utilising Beactica's platform to support the progress of one of their prioritized programmes" said Beactica CEO, Dr. Per Källblad. "Fragment-based approaches to drug discovery are creating new pathways towards small-molecule leads of high-quality and Beactica has worked hard to win a reputation for being at the cutting-edge of advances".
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.